Sentiment Summary
Recent Events
Ex-dividend date for the final dividend of HK$0.25 per share on 2026-07-20 scheduled, with payment on 2026-08-04; low importance as dividend adjustments typically result in <5% price impact.
Ex-dividend date on June 3, 2026 for a proposed final dividend of RMB 0.5390 and a special dividend of RMB 0.6714 (AGM: May 28, Record Date: June 8); ≥5% price impact scheduled.
Full 48-week biopsy results from the Phase 2 clinical trial of the MASH treatment 'DD01' are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 on May 31, 2026. Estimated price impact ≥10% due to significant potential for a global partnership deal, scheduled.
Q1 2026 earnings release on May 18, 2026, with an estimated 5% market impact from R&D and pipeline updates, scheduled.
The final dividend for FY2025 of RMB 15.7927 per 10 shares will trade ex-dividend on May 13, 2026. Low importance is estimated as the ex-dividend price adjustment is typically around 1-2%, scheduled.
On 2026-05-12, announced a global strategic collaboration and license agreement with Bristol-Myers Squibb (BMY) covering 13 early-stage programs in oncology, hematology, and immunology with potential milestones of $15.2 billion; this massive deal is estimated to have a >10% price impact.
Genscript made a voluntary announcement regarding the Q1 2026 financial results of its associate company, Legend Biotech, which were filed on May 12, 2026; medium importance reflects the impact of a major associate's performance on the company's valuation.
At the Annual General Meeting on 2026-05-12, shareholders approved all resolutions, including a general mandate authorizing the company to repurchase up to 10% of its issued shares.
Exclusive strategic collaboration with GSK to commercialize bepirovirsen in mainland China on 2026-05-11; high impact expected from first-in-class therapy market potential, scheduled
Hanmi Pharm announced a major organizational restructuring to focus on its 2030 mid-to-long-term growth strategy, particularly the obesity treatment pipeline, scheduled. Low impact estimated as organizational changes typically have delayed market effects.
Announced on 2026-05-10 that China's NMPA granted a third Breakthrough Therapy Designation (BTD) for IBI363; Medium importance estimated due to expedited regulatory path.
The company's self-developed B7-H3 targeted antibody-drug conjugate (ADC), HS-20093, was granted Breakthrough Therapy Designation by China's NMPA for treating esophageal squamous cell carcinoma on May 9, 2026, with the announcement made on May 11, 2026.
Announced on 2026-05-08 that China's NMPA approved the Mazdutide pre-filled multi-dose pen; Medium importance estimated due to enhanced product convenience.
Alteogen Q1 2026 earnings release (Revenue KRW 71.6B, OP KRW 39.3B) on 2026-05-08 expected; neutral impact estimated as YoY decrease is offset by upfront payments from new licensing deals.
ABL Bio announced Q1 2026 earnings, reporting revenue of KRW 13.1 billion (up from KRW 2.2 billion in Q1 2025) and a narrowed operating loss of KRW 17.2 billion. Medium importance estimated due to significant financial improvement.
The supplemental New Drug Application (sNDA) for Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab for 1L PD-L1+ NSCLC was accepted by China's NMPA on May 8, 2026. This key pipeline progress is estimated to have a ≥5% price impact expected.
Yuhan to present positive results from the Phase 1 clinical trial of YH35995 for Gaucher disease at the IWGGD symposium (2026-05-08); importance is Low as Phase 1 results typically have limited immediate market impact, scheduled.
On 2026-05-08, announced clinical trial approval notices from China's NMPA for five drugs, including HRS-6093 tablets and Injectable SHR-1826; these regulatory approvals are estimated to have a >1% price impact.
Announced on 2026-05-07 that its independently developed Class 1 innovative drug, UBT38006 injection (a long-acting weekly insulin formulation), received implied permission for clinical trials from China's National Medical Products Administration (NMPA).
Yuhan announced an API supply contract worth KRW 56 billion with BridgeBio Pharma for a cardiomyopathy treatment (2026-05-07), with the contract period from May 2026 to March 2028; importance is Low as the contract value is small relative to annual revenue, scheduled.